According to the 2016 World Health Organization (WHO) classification criteria, mutation in the gene encoding isocitrate dehydrogenase (IDH) enzyme has been identified in the sub-stratification of glioma (1). This evidence concerns the gene IDH2 and central nervous system cancer.